S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in
NASDAQ:REPH

Recro Pharma Stock Forecast, Price & News

$3.28
-0.36 (-9.90 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.98
Now: $3.28
$3.67
50-Day Range
$2.96
MA: $3.80
$5.04
52-Week Range
$1.49
Now: $3.28
$10.07
Volume865,259 shs
Average Volume842,922 shs
Market Capitalization$77.44 million
P/E Ratio16.38
Dividend YieldN/A
Beta1.25
Recro Pharma, Inc. a contract development and manufacturing organization, engages in the development, manufacturing, and packaging of oral solid dose drug products to pharmaceutical market in the United States and internationally. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.
Recro Pharma logo

Headlines

Earnings Preview for Recro Pharma
February 25, 2021 |  finance.yahoo.com
Revisiting Recro Pharma
February 17, 2021 |  seekingalpha.com
Recro Grants Inducement Award to New Chief Executive Officer
December 18, 2020 |  finance.yahoo.com
Recro Announces Executive Changes
December 16, 2020 |  finance.yahoo.com
Oppenheimer Says These 2 Stocks Could Spike Over 100%
December 11, 2020 |  finance.yahoo.com
Recro Pharma (REPH) Q3 2020 Earnings Call Transcript
November 9, 2020 |  finance.yahoo.com
Recro Pharma EPS misses by $0.09, misses on revenue
August 10, 2020 |  seekingalpha.com
Recro Reports Second Quarter 2020 Financial Results
August 10, 2020 |  finance.yahoo.com
Recro Pharma: Q2 Earnings Insights
August 10, 2020 |  finance.yahoo.com
Is Recro Pharma Inc (REPH) A Good Stock To Buy?
July 5, 2020 |  finance.yahoo.com
Recro Pharma down 41% on tough Q1, guidance cut
May 11, 2020 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:REPH
CUSIPN/A
Phone484-395-2470
Employees213
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$99.22 million
Cash Flow$0.64 per share
Book Value($0.30) per share

Profitability

Net Income$-18,630,000.00

Miscellaneous

Market Cap$77.44 million
Next Earnings Date5/10/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.76 out of 5 stars

Medical Sector

185th out of 1,972 stocks

Pharmaceutical Preparations Industry

85th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.9 5 -4 -3 -2 -1 -
$3.28
-0.36 (-9.90 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive REPH News and Ratings via Email

Sign-up to receive the latest news and ratings for REPH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Recro Pharma (NASDAQ:REPH) Frequently Asked Questions

Is Recro Pharma a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Recro Pharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Recro Pharma stock.
View analyst ratings for Recro Pharma
or view top-rated stocks.

What stocks does MarketBeat like better than Recro Pharma?

Wall Street analysts have given Recro Pharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Recro Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Recro Pharma?

Recro Pharma saw a increase in short interest in the month of January. As of January 29th, there was short interest totaling 1,440,000 shares, an increase of 47.9% from the January 14th total of 973,600 shares. Based on an average daily volume of 1,130,000 shares, the short-interest ratio is presently 1.3 days. Approximately 7.3% of the shares of the stock are sold short.
View Recro Pharma's Short Interest
.

When is Recro Pharma's next earnings date?

Recro Pharma is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Recro Pharma
.

How were Recro Pharma's earnings last quarter?

Recro Pharma, Inc. (NASDAQ:REPH) released its earnings results on Friday, February, 26th. The specialty pharmaceutical company reported ($0.48) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.26) by $0.22.
View Recro Pharma's earnings history
.

How has Recro Pharma's stock been impacted by COVID-19 (Coronavirus)?

Recro Pharma's stock was trading at $9.17 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, REPH shares have decreased by 64.3% and is now trading at $3.2750.
View which stocks have been most impacted by COVID-19
.

What guidance has Recro Pharma issued on next quarter's earnings?

Recro Pharma issued an update on its first quarter 2021 Pre-Market earnings guidance on Friday, February, 26th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $16.356-16.852 million, compared to the consensus revenue estimate of $17.64 million.

What price target have analysts set for REPH?

2 brokerages have issued 1 year price objectives for Recro Pharma's shares. Their forecasts range from $12.00 to $12.00. On average, they expect Recro Pharma's share price to reach $12.00 in the next year. This suggests a possible upside of 266.4% from the stock's current price.
View analysts' price targets for Recro Pharma
or view top-rated stocks among Wall Street analysts.

Who are Recro Pharma's key executives?

Recro Pharma's management team includes the following people:
  • Mr. Ryan D. Lake, Chief Financial Officer (Age 44, Pay $572.13k)
  • Mr. J. David Enloe Jr., Pres, CEO & Director (Age 57)
  • Mr. Randall J. Mack, Sr. VP of Devel. (Age 56)
  • Mr. Marshall Rizzo M.B.A., Exec. VP & GM of Contract Manufacturing Facility
  • Dr. Jyrki Mattila, Exec. VP of Bus. Devel. (Age 66)
  • Carla Lusby, Corp. Sec.

Who are some of Recro Pharma's key competitors?

What other stocks do shareholders of Recro Pharma own?

What is Recro Pharma's stock symbol?

Recro Pharma trades on the NASDAQ under the ticker symbol "REPH."

Who are Recro Pharma's major shareholders?

Recro Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (5.84%), BlackRock Inc. (5.72%), Alyeska Investment Group L.P. (3.12%), Alyeska Investment Group L.P. (3.12%), Russell Investments Group Ltd. (2.40%) and Northern Trust Corp (1.06%). Company insiders that own Recro Pharma stock include Arnaud Ajdler, Geraldine Henwood and Scp Vitalife Partners (Israel).
View institutional ownership trends for Recro Pharma
.

Which major investors are selling Recro Pharma stock?

REPH stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Alyeska Investment Group L.P., Alyeska Investment Group L.P., Renaissance Technologies LLC, Northern Trust Corp, Wells Fargo & Company MN, Dimensional Fund Advisors LP, and Engineers Gate Manager LP. Company insiders that have sold Recro Pharma company stock in the last year include Geraldine Henwood, and Scp Vitalife Partners (Israel).
View insider buying and selling activity for Recro Pharma
or view top insider-selling stocks.

Which major investors are buying Recro Pharma stock?

REPH stock was purchased by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Boston Partners, Essex Investment Management Co. LLC, Clear Harbor Asset Management LLC, BlackRock Inc., Virtu Financial LLC, JPMorgan Chase & Co., and Squarepoint Ops LLC.
View insider buying and selling activity for Recro Pharma
or or view top insider-buying stocks.

How do I buy shares of Recro Pharma?

Shares of REPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Recro Pharma's stock price today?

One share of REPH stock can currently be purchased for approximately $3.28.

How much money does Recro Pharma make?

Recro Pharma has a market capitalization of $77.44 million and generates $99.22 million in revenue each year. The specialty pharmaceutical company earns $-18,630,000.00 in net income (profit) each year or $0.20 on an earnings per share basis.

How many employees does Recro Pharma have?

Recro Pharma employs 213 workers across the globe.

What is Recro Pharma's official website?

The official website for Recro Pharma is www.recropharma.com.

Where are Recro Pharma's headquarters?

Recro Pharma is headquartered at 490 LAPP ROAD, MALVERN PA, 19355.

How can I contact Recro Pharma?

Recro Pharma's mailing address is 490 LAPP ROAD, MALVERN PA, 19355. The specialty pharmaceutical company can be reached via phone at 484-395-2470 or via email at [email protected]


This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.